Life Sciences

The need for alignment to achieve health outcomes for all

As populations age and chronic diseases become commonplace, health care will take an ever larger share of GDP. Scientific progress, augmented intelligence and a more empowered patient are driving changes in the delivery of health care to a personalized experience that demands health outcomes as the core metric. This is causing a power shift among traditional stakeholder groups, with new entrants (often not driven by profit) disrupting incumbents.

Innovation, productivity and access to patients remain the industry’s biggest challenges. These trends challenge the capital strategy of every link in the life sciences value chain, from R&D and product supply to product launch and patient-centric operating models.

Our Global Life Sciences Sector brings together a worldwide network of 11,000 sector-focused professionals to anticipate trends, identify their implications and help our clients create competitive advantage. We can help you navigate your way forward and achieve sustainable success in the new health-outcomes-driven ecosystem.




Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

Pharmaceutical R&D tax incentives

EY - Global Life Sciences - Tax Law video

Globalization of the pharmaceutical industry and increased outsourcing have drastically changed the R&D landscape. This report explores the impact on R&D tax incentives.


EY Life Sciences: Tax Law video

EY - Global Life Sciences - Tax Law video

EY's Virginie Lefebvre-Dutilleul tells us about how EY's legal credentials can add value to our work with life sciences clients. Services described in video cannot be provided by member firms in certain jurisdictions such as the United States.


EY-Applying IFRS 10 and IFRS 11

Applying IFRS 10 and IFRS 11

How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.